Resveratrol-3,4',5-trihydroxy-trans-stillbene (resveratrol; RSV), a natural non-flavonoid polyphenol compound, provides protection against stress injury, excessive sunlight, ultraviolet radiation, infections, and invading fungi. There is increasing evidence that resveratrol, a sirtuin1 activator, plays a pivotal role in neuroprotection and neuronal differentiation. In this study, we investigated whether resveratrol induces neuronal differentiation of human bone marrow-mesenchymal stem cells (hBM-MSCs). Quantitative PCR results showed that resveratrol-treated MSCs (RSV-MSCs) had significantly increased expression of the neuroprogenitor markers Nestin, Musashi, CD133, and GFAP. When RSV-MSCs were differentiated with neuronal induction media (RSV-dMSCs), they exhibited a cell body and dendritic morphology similar to neurons. The number and neurite length of these RSV-dMSCs were significantly increased compared to differentiated MSCs (dMSCs). The RSV-dMSCs and dMSCs had significantly increased expression of the neuronal-specific marker genes Nestin, Musashi, CD133, GFAP, NF-M, MAP-2, and KCNH1. The RSV-dMSCs also showed a higher expression of the neuronal marker proteins, Nestin and NF-M, based on immunocytochemical staining and immunoblot analysis. This effect was abolished by the treatment of sirtuin1 inhibitor EX527. Therefore, we have shown that resveratrol treatment, along with the use of neuronal induction media, effectively stimulates neuronal cell differentiation of hBM-MSCs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neulet.2014.10.024 | DOI Listing |
Invest Ophthalmol Vis Sci
December 2024
Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
Purpose: This review explores the role of pigment epithelium-derived factor (PEDF) in retinal degenerative and vascular disorders and assesses its potential both as an adjunct to established vascular endothelial growth factor inhibiting treatments for retinal vascular diseases and as a neuroprotective therapeutic agent.
Methods: A comprehensive literature review was conducted, focusing on the neuroprotective and anti-angiogenic properties of PEDF. The review evaluated its effects on retinal health, its dysregulation in ocular disorders, and its therapeutic application in preclinical models.
NeuroSci
December 2024
Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91070, Mexico.
Exposure to valproic acid (VPA) during embryogenesis has become a valuable tool for modeling neurodevelopmental disorders in animal models such as zebrafish (). This article examines the effects of embryonic exposure to VPA in zebrafish on the basis of 39 articles sourced from PubMed and Google Scholar. We conducted a systematic review and meta-analysis to elucidate the common impacts of VPA exposure and reported that VPA significantly altered development at various levels.
View Article and Find Full Text PDFFront Neurosci
December 2024
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Background: Extracellular vesicles are easily accessible in various biofluids and allow the assessment of disease-related changes in the proteome. This has made them a promising target for biomarker studies, especially in the field of neurodegeneration where access to diseased tissue is very limited. Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson's disease.
View Article and Find Full Text PDFScand J Immunol
January 2025
Department of Neurology, the Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Fas has been shown to positively regulate the differentiation of T helper 17 (Th17) cells in mouse models of experimental autoimmune encephalomyelitis (EAE). Fas protein expression is regulated by ubiquitination but has not been further studied. In this study, we investigated the role of the Fas ubiquitin ligase in Th17 cell differentiation and highlighted its potential as a therapeutic target for EAE.
View Article and Find Full Text PDFTransl Neurodegener
December 2024
Department of Anatomy and Medical Imaging, University of Auckland, 85 Park Road, Grafton, , Auckland, 1142, New Zealand.
Background: Parkinson's disease (PD) and multiple system atrophy (MSA) are classified as α-synucleinopathies and are primarily differentiated by their clinical phenotypes. Delineating these diseases based on their specific α-synuclein (α-Syn) proteoform pathologies is crucial for accurate antemortem biomarker diagnosis. Newly identified α-Syn pathologies in PD raise questions about whether MSA exhibits a similar diversity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!